2023 - Research.com Medicine in France Leader Award
Martin Schlumberger mainly investigates Internal medicine, Thyroid cancer, Thyroid, Endocrinology and Thyroid carcinoma. His Internal medicine research integrates issues from Gastroenterology, Surgery and Oncology. He is interested in Follicular thyroid cancer, which is a field of Thyroid cancer.
His Thyroid research is multidisciplinary, incorporating perspectives in Hormone and Carcinoma, Lymph node, Pathology. Martin Schlumberger has researched Endocrinology in several fields, including Survival rate and Institut Gustave Roussy. Martin Schlumberger mostly deals with Papillary thyroid cancer in his studies of Thyroid carcinoma.
His primary areas of investigation include Internal medicine, Thyroid cancer, Thyroid, Thyroid carcinoma and Endocrinology. His studies deal with areas such as Gastroenterology, Surgery and Oncology as well as Internal medicine. Martin Schlumberger focuses mostly in the field of Thyroid cancer, narrowing it down to topics relating to Thyroidectomy and, in certain cases, Neck dissection.
His study looks at the relationship between Thyroid and fields such as Lymph node, as well as how they intersect with chemical problems. His work in Thyroid carcinoma addresses subjects such as Nuclear medicine, which are connected to disciplines such as Radiology. His study in the field of Thyroid peroxidase is also linked to topics like Context.
Martin Schlumberger mostly deals with Thyroid cancer, Internal medicine, Oncology, Thyroid and Refractory. He has included themes like Thyroid carcinoma, Radioactive iodine, Surgery and Thyroglobulin in his Thyroid cancer study. His Thyroid carcinoma research is multidisciplinary, incorporating elements of Urology and Pathology.
Martin Schlumberger works mostly in the field of Internal medicine, limiting it down to concerns involving Endocrinology and, occasionally, Radiation therapy. His biological study deals with issues like Medullary thyroid cancer, which deal with fields such as Cabozantinib. His research investigates the connection between Thyroid and topics such as Carcinoma that intersect with issues in Radiology.
His scientific interests lie mostly in Thyroid cancer, Internal medicine, Thyroid, Oncology and Surgery. His Thyroid cancer research includes themes of Levothyroxine, Carcinoma, Retrospective cohort study and Thyroglobulin. His study focuses on the intersection of Internal medicine and fields such as Endocrinology with connections in the field of DNA damage.
Martin Schlumberger works on Thyroid which deals in particular with Thyroid carcinoma. Martin Schlumberger combines subjects such as Latency stage and Urology with his study of Thyroid carcinoma. His Surgery study which covers Sorafenib that intersects with Weight loss.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R. Haugen;Erik K. Alexander;Keith C. Bible;Gerard M. Doherty.
Thyroid (2009)
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
David S. Cooper;Gerard M. Doherty;Bryan R. Haugen;Richard T. Kloos.
Thyroid (2009)
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
Furio Pacini;Martin Schlumberger;Henning Dralle;Rossella Elisei.
European Journal of Endocrinology (2006)
Papillary and follicular thyroid carcinoma.
Martin Jean Schlumberger.
The New England Journal of Medicine (1998)
Revised American thyroid association guidelines for the management of medullary thyroid carcinoma
Samuel A Wells;Sylvia L Asa;Henning Dralle;Rossella Elisei.
Thyroid (2015)
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy
C. Durante;N. Haddy;E. Baudin;S. Leboulleux.
The Journal of Clinical Endocrinology and Metabolism (2006)
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger;Makoto Tahara;Lori J. Wirth;Bruce Robinson.
The New England Journal of Medicine (2015)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells;Bruce G. Robinson;Robert F. Gagel;Henning Dralle.
Journal of Clinical Oncology (2012)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S Brose;Christopher M Nutting;Barbara Jarzab;Rossella Elisei.
The Lancet (2014)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei;Martin J. Schlumberger;Stefan P. Müller;Patrick Schöffski.
Journal of Clinical Oncology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Institut Gustave Roussy
Institut Gustave Roussy
University of Siena
The University of Texas MD Anderson Cancer Center
University of Pisa
Sapienza University of Rome
Institut Gustave Roussy
Royal North Shore Hospital
University of Paris-Saclay
University of Milan
Khalifa University
University of Antwerp
Shandong Normal University
University of Maryland, College Park
University of Florida
Northwestern Polytechnical University
Université Laval
National Institute for Environmental Studies
La Trobe University
University of Central Florida
University of Illinois at Chicago
University at Buffalo, State University of New York
The University of Texas Health Science Center at Houston
University of Glasgow
University of Amsterdam
University of Groningen